RxSight Inc., an Aliso Viejo maker of implantable eye lenses, fell as much as 32% in after-hours trading after revising downward its annual forecast.
The company forecast 2025 sales of $120 million to $130 million, below the prior guidance for $160 million to $175 million; analysts expected $167.6 million. It also said second-quarter sales were $33.6 million; analysts expected $39.8 million.
“Guided by insights from our second quarter underperformance and building on our long-term vision, we are evolving our commercial approach to re-direct more of our focus toward supporting customer success within new and existing practices,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight.
Shares fell 33% to $8.59 in after-hours trading. They ended regular trading today at $12.79 and a $520 million market cap (Nasdaq: RXST).